期刊文献+

孕妇HBV-DNA定量与母婴垂直传播的临床研究 被引量:4

Clinical study on HBV-DNA quantification in pregnant women and mother-to-fetus vertical transmission
原文传递
导出
摘要 目的探讨抗病毒药物替诺福韦酯阻断HBV母婴传播的有效性,为更有效地阻断HBV母婴传播提供科学依据。方法将85例HBs Ag阳性孕妇分为观察组50例(愿意接受阻断治疗)和对照组35例(不愿意接受阻断治疗),观察组孕妇分别在第28、32、36周给予300 mg/d替诺福韦酯口服,分别检测两组孕妇28、32、36周及分娩时血清中HBV-DNA载量及新生儿HBV感染率,并对新生儿随访3、6、12个月检测新生儿HBs Ag、抗HBs阳性率。结果观察组孕妇32、36周及分娩时血清中HBV-DNA载量显著低于对照组,新生儿感染率显著低于对照组,差异均有统计学意义(P<0.05)。随访结果显示,观察组新生儿3、6、12个月HBs Ag阳性率显著低于对照组,3、6个月抗HBs阳性率则高于对照组,差异均有统计学意义(P<0.05)。结论替诺福韦酯可以在一定程度上阻断HBV的母婴传播,值得临床鼓励HBV感染孕妇应用。 Objective To explore the effectiveness of tenofovir disoproxil fumarate in blocking HBV mother-to-fetus vertical transmission,provide a scientific basis for effective blocking of HBV mother-to-fetus vertical transmission. Methods Eighty-five pregnant women with positive HBs Ag were divided into observation group( 50 cases receiving blocking therapy) and control group( 35 cases not receiving blocking therapy). The cases in observation group were treated by oral administration of tenofovir disoproxil fumarate( 300 mg/d) during the 28 th,the 32 nd,and the 36 th weeks of pregnancy. HBV-DNA loads in serum and HBV infection rates of neonates during the 28 th,the32 nd,and the 36 th weeks of pregnancy and at birth in the two groups were detected,respectively. The positive rates of Hbs Ag and anti-HBs among the neonates at 3,6,and 12 months after birth were followed up. Results HBV-DNA loads in serum during the 2 nd and the 36 th weeks of pregnancy and at birth and HBV infection rate of neonates in observation group were statistically significantly lower than those in control group( P〈0. 05). The positive rates of Hbs Ag among the neonates at 3,6,and 12 months after birth in observation group were statistically significantly lower than those in control group( P〈0. 05). The positive rates of anti-HBs among the neonates at 3 and 6 months after birth in observation group were statistically significantly higher than those in control group( P〈0. 05). Conclusion Tenofovir disoproxil fumarate can block HBV mother-to-fetus vertical transmission to a certain extent,and it is worthy of clinical application among HBV-infected pregnant women.
出处 《中国妇幼保健》 CAS 2018年第6期1239-1241,共3页 Maternal and Child Health Care of China
关键词 替诺福韦酯 母婴传播 乙型肝炎病毒 阻断 Tenofovir disoproxil fumarate Mother-to-fetus vertical transmission HBV Blocking
  • 相关文献

参考文献7

二级参考文献54

共引文献58

同被引文献48

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部